Experimental Pharmacological Management of Psoriasis

Psoriasis is a chronic, relapsing, immune-mediated systemic disease. Its pathogenesis is complex and not fully understood yet. Genetic and epigenetic factors interact with molecular pathways involving TNF-[alpha], IL-23/IL-17 axis, and peculiar cytokines, as IL-36 or phosphodiesterase 4. This review...

Full description

Saved in:
Bibliographic Details
Published in:Journal of experimental pharmacology 2021-07, Vol.13, p.725-737
Main Authors: Campione, Elena, Cosio, Terenzio, Prete, Monia Di, Lanna, Caterina, Dattola, Annunziata, Bianchi, Luca
Format: Article
Language:English
Subjects:
B cells
Binding sites
Clinical trials
Cytokines
Development and progression
Health aspects
Hyperplasia
il-36 receptors inhibitors
janus kinase inhibitor
Metabolism
Neutrophils
Pathogenesis
phosphodiesterase 4 inhibitor
Psoriasis
Review
Skin
Tyrosine
tyrosine kinase 2 inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a chronic, relapsing, immune-mediated systemic disease. Its pathogenesis is complex and not fully understood yet. Genetic and epigenetic factors interact with molecular pathways involving TNF-[alpha], IL-23/IL-17 axis, and peculiar cytokines, as IL-36 or phosphodiesterase 4. This review discusses the mechanisms involved in the development of the disease, as well as the therapeutic options proposed following the investigation of the inflammatory psoriatic pathways. We performed a comprehensive search using the words "psoriasis" and the newest molecules currently under investigation and approval. From these data, a new scenario in psoriasis is occurring to personalize the therapies--especially systemic ones and those using small molecules--and avoid topical and injectable drugs. We reported the newest therapeutic opportunities, including the inhibitors of Janus kinase/ tyrosine kinase 2, phosphodiesterase-4 and IL-36 receptor. Today, more than 20 molecules are under investigation for the treatment of cutaneous psoriasis. Most of them are constituted by small molecules or biologic therapies. This underlines how psoriasis needs systemic therapies, due to its complex pathogenesis and multisystemic involvement. Keywords: psoriasis, janus kinase inhibitors, tyrosine kinase 2 inhibitors, phosphodiesterase 4 inhibitors, IL-36 receptors inhibitors
ISSN:1179-1454
1179-1454
DOI:10.2147/JEP.S265632